Paratek Investor Webinar: A Global Opportunity In NTM
About The Event
Join us for an Investor Event with Paratek Pharmaceuticals focusing on the global opportunity for omadacycline in Non-Tuberculous Mycobacteria (NTM). The event features Patrick Flume, MD (Medical University and Cystic Fibrosis Center of South Carolina), who will present an overview of NTM and the current treatment landscape, unmet need and value of new oral options in the United States, and Jakko van Ingen, MD, PhD (Radboud University Medical Center, The Netherlands) who will discuss the global challenges and epidemiology of the disease. Paratek has received significant inbound interest from the scientific community on the potential utility of omadacycline for this serious, chronic orphan disease.
Paratek’s management team will provide a brief corporate overview including a review of the global addressable market opportunity for omadacycline in NTM, including both M. abscessus and Mycobacterium Avium Complex (MAC) patient subtypes. An update on the company’s ongoing data generation and clinical development program for omadacycline for the treatment of NTM pulmonary disease caused by M. abscessus will also be provided. Paratek is currently enrolling patients in the first ever randomized, placebo-controlled Phase 2b clinical trial for NTM pulmonary disease caused by M. abcessus.
NUZYRA® (omadacycline) is a once-daily oral and intravenous antibiotic approved by the FDA for the treatment of adults with Community-Acquired Bacterial Pneumonia (CABP) and Acute Bacterial Skin and Skin Structure Infections (ABSSSI).
A live Q&A session will follow the formal presentations.